Great Science
Deep Compassion
Real Impact
Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.
Featured News
February 08, 2024
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
.png)
Action for Good
More than 200 Alkermes employees recently took time out of their normal work day to contribute their time and talents to a variety of local Massachusetts nonprofit organizations as part of our fifteenth Alkermes in Action employee volunteer day.
Inspiring Inclusion
In celebration of International Women's Day, three senior female leaders at Alkermes reflected on their career journeys and their efforts to inspire inclusion.
.png){kind=logo}
Driven by Passion
Alkermes employees work with urgency -- in the laboratory, in the clinic and in the community -- seeking to make a meaningful difference for people living with complex and difficult-to-treat diseases. For many of our employees, this work is part of their personal mission to help patients, families and communities.
R&D Pipeline
We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
-
Olanzapine and samidorphan
-
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
OverviewOlanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Clinical TrialsOlanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
-
-
ALKS 2680
-
Narcolepsy Type 1
Phase 3
-
Narcolepsy Type 2
Phase 1
OverviewALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy.
Clinical TrialsALKS 2680 is currently being evaluated in the Vibrance-1 phase 2 study in adults with narcolepsy type 1. For more information about this study, please visit vibrancestudies.com (for U.S. audiences only) and clinicaltrials.gov/study/NCT06358950.
ALKS 2680 was previously evaluated in a phase 1 study in healthy volunteers, and in adults with narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia. -
-
Orexin Agonists
-
Neuroscience Indications
Discovery
OverviewAdditional orexin 2 agonists are in discovery for excessive daytime sleepiness disorders and other neuropsychiatric disorders.
-
